Brain Melanocortin Receptors Crucial for Stress-Induced Appetite Suppression in Mice
Background
Stress is a well-known factor that can profoundly impact appetite and eating behaviors, often leading to a reduction in food intake, a condition sometimes referred to as stress-induced anorexia. The brain's melanocortin system, particularly melanocortin receptors (MCRs), plays a critical role in regulating energy balance and feeding. However, the precise involvement of brain melanocortin receptors in mediating the suppression of food intake specifically under acute ether stress conditions remained unclear.
Results
The study revealed that acute ether stress significantly reduced food intake in mice, showing a 48% decrease compared to non-stressed controls (p<0.001). Administration of the melanocortin receptor agonist, MTII, further exacerbated this effect, leading to an additional 22% reduction in food intake in stressed mice (p<0.05). Conversely, pretreatment with the melanocortin receptor antagonist, SHU9119, partially but significantly reversed the stress-induced appetite suppression. SHU9119 increased food intake by 35% in ether-stressed mice compared to stressed controls receiving saline (p<0.01), indicating a crucial role for MCR activation in this response. These findings suggest that the activation of brain melanocortin receptors is a key mechanism underlying the acute stress-induced suppression of appetite.
Why It Matters
These findings significantly advance our understanding of the neurobiological mechanisms linking stress and appetite regulation. The study highlights the melanocortin system as a central mediator of stress-induced anorexia, providing a potential therapeutic target. This research could pave the way for developing novel pharmacological interventions for conditions like stress-related eating disorders, anorexia nervosa, or cachexia where appetite suppression is a major concern. Future research should focus on identifying the specific MCR subtypes involved and validating these findings in chronic stress models and eventually, human clinical trials (e.g., Phase I/II).